Potential applications of P2X3 receptor antagonists in the treatment of refractory cough.

[1]  Laura R. Sadofsky,et al.  Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening , 2022, Membranes.

[2]  J. Smith,et al.  Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study , 2022, Clinical Pharmacokinetics.

[3]  I. Gashaw,et al.  First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics , 2022, British journal of clinical pharmacology.

[4]  A. Markham.  Gefapixant: First Approval , 2022, Drugs.

[5]  I. Pavord,et al.  Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials , 2022, The Lancet.

[6]  Augustine S. Lee,et al.  A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough , 2022, ERJ Open Research.

[7]  J. Bousquet,et al.  WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways , 2021, The World Allergy Organization journal.

[8]  S. Birring,et al.  Chronic cough: new insights and future prospects , 2021, European Respiratory Review.

[9]  Yoshio Yamamoto,et al.  Morphology and chemical characteristics of taste buds associated with P2X3‐immunoreactive afferent nerve endings in the rat incisive papilla , 2021, Journal of anatomy.

[10]  T. Kamei,et al.  Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough , 2021, European Respiratory Journal.

[11]  S. Boyce,et al.  Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers , 2021, Scientific Reports.

[12]  H. Kai,et al.  Discovery of clinical candidate Sivopixant (S-600918): lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists. , 2021, Bioorganic & medicinal chemistry letters.

[13]  G. Guyatt,et al.  Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework , 2021, European Respiratory Review.

[14]  K. Ahuja,et al.  TRPV1 Activation by Capsaicin Mediates Glucose Oxidation and ATP Production Independent of Insulin Signalling in Mouse Skeletal Muscle Cells , 2021, Cells.

[15]  E. Nisenbaum,et al.  Antitussive effects of NaV 1.7 blockade in guinea pigs. , 2021, European journal of pharmacology.

[16]  S. Birring,et al.  Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study , 2021, The European respiratory journal.

[17]  V. Moiseenkova-Bell,et al.  Structural pharmacology of TRP channels. , 2021, Journal of molecular biology.

[18]  Lu-Yuan Lee,et al.  TRP channels in airway sensory nerves , 2021, Neuroscience Letters.

[19]  T. Itoh,et al.  Dioxotriazine derivatives as a new class of P2X3 receptor antagonists: Identification of a lead and initial SAR studies. , 2021, Bioorganic & medicinal chemistry letters.

[20]  M. van Faassen,et al.  The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs , 2020, Respiratory Research.

[21]  B. Beghé,et al.  Management of chronic refractory cough in adults , 2020, European Journal of Internal Medicine.

[22]  M. Machida,et al.  Design of phase 2b randomised controlled trial of S-600918, P2X3 receptor antagonist for refractory chronic cough , 2020 .

[23]  Z. Qiu,et al.  Gabapentin versus baclofen for treatment of refractory gastroesophageal reflux-induced chronic cough , 2020, Journal of thoracic disease.

[24]  S. Mazzone,et al.  Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough , 2020, Clinical pharmacology and therapeutics.

[25]  A. Niimi,et al.  Phase 2a Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a P2x3 Receptor Antagonist S-600918: Effects on Health-Related Quality of Life in Patients with Refractory Chronic Cough , 2020 .

[26]  M. Belvisi,et al.  Novel airway smooth muscle–mast cell interactions and a role for the TRPV4-ATP axis in non-atopic asthma , 2020, European Respiratory Journal.

[27]  S. Birring,et al.  Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. , 2020, The Lancet. Respiratory medicine.

[28]  J. Smith,et al.  Gefapixant in two randomised dose-escalation studies in chronic cough , 2020, European Respiratory Journal.

[29]  K. Lai,et al.  Current Status and Future Directions of Chronic Cough in China , 2020, Lung.

[30]  S. Birring,et al.  ERS guidelines on the diagnosis and treatment of chronic cough in adults and children , 2019, European Respiratory Journal.

[31]  P. Geppetti,et al.  Ion Channel Pharmacology for Pain Modulation. , 2019, Handbook of experimental pharmacology.

[32]  S. Birring,et al.  S27 A placebo-controlled, double-blind, randomised, crossover study to assess the efficacy, safety and tolerability of TRPV4 inhibitor GSK2798745 in participants with chronic cough , 2019, What’s new? Clinical trials in lung disease.

[33]  A. Niimi,et al.  Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough , 2019, Airway pharmacology and treatment.

[34]  J. Smith,et al.  Cough: New Pharmacology. , 2019, The journal of allergy and clinical immunology. In practice.

[35]  J. Gever,et al.  Action of MK‐7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation , 2019, British journal of pharmacology.

[36]  N. Chauret,et al.  BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. , 2019, Pulmonary pharmacology & therapeutics.

[37]  A. Morice,et al.  The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study , 2019, European Respiratory Journal.

[38]  H. Kai,et al.  Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds. , 2019, Bioorganic & medicinal chemistry letters.

[39]  N. Chaudhari,et al.  Transcriptomes and neurotransmitter profiles of classes of gustatory and somatosensory neurons in the geniculate ganglion , 2017, Nature Communications.

[40]  S. Birring,et al.  Inhibition of P2X3 by MK-7264 reduces 24-hour cough frequency in a randomized, controlled, Phase 2b clinical trial , 2017 .

[41]  J. Smith,et al.  Effects of a novel sodium channel blocker, GSK2339345, in patients with refractory chronic cough
. , 2017, International journal of clinical pharmacology and therapeutics.

[42]  M. Belvisi,et al.  Cough and airway disease: The role of ion channels. , 2017, Pulmonary pharmacology & therapeutics.

[43]  J. Smith,et al.  LATE-BREAKING ABSTRACT: Tackling the burden of chronic cough: A dose escalation study of AF-219 , 2016 .

[44]  J. Smith,et al.  Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphate , 2016, The Journal of allergy and clinical immunology.

[45]  D. Smallwood,et al.  Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control , 2016, Thorax.

[46]  A. Morice.  Over-the-counter cough medicines: New approaches. , 2015, Pulmonary pharmacology & therapeutics.

[47]  K. Chung,et al.  NMDA and GABA receptors as potential targets in cough hypersensitivity syndrome. , 2015, Current opinion in pharmacology.

[48]  Gary Layton,et al.  P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study , 2015, The Lancet.

[49]  S. Birring,et al.  The Impact of Chronic Cough: A Cross-Sectional European Survey , 2015, Lung.

[50]  M. Khosravi,et al.  A synergistic effect of simultaneous TRPA1 and TRPV1 activations on vagal pulmonary C-fiber afferents. , 2015, Journal of applied physiology.

[51]  N. Ryan.  A review on the efficacy and safety of gabapentin in the treatment of chronic cough , 2015, Expert opinion on pharmacotherapy.

[52]  C. T. French,et al.  Overview of the management of cough: CHEST Guideline and Expert Panel Report. , 2014, Chest.

[53]  S. Birring,et al.  Expert opinion on the cough hypersensitivity syndrome in respiratory medicine , 2014, European Respiratory Journal.

[54]  B. Undem,et al.  Targeting Voltage Gated Sodium Channels NaV1.7, NaV1.8, and NaV1.9 for Treatment of Pathological Cough , 2014, Lung.

[55]  A. Ford,et al.  The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders , 2013, Front. Cell. Neurosci..

[56]  M. Carr.  Regulation of cough and action potentials by voltage-gated Na channels. , 2013, Pulmonary pharmacology & therapeutics.

[57]  S. Birring,et al.  Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[58]  A. Ford,et al.  A role for ATP in bronchoconstriction‐induced activation of guinea pig vagal intrapulmonary C‐fibres , 2012, The Journal of physiology.

[59]  T. Finger,et al.  Residual chemoresponsiveness to acids in the superior laryngeal nerve in "taste-blind" (P2X2/P2X3 double-KO) mice. , 2012, Chemical senses.

[60]  I. Delescluse,et al.  Inhibition of airway hyper‐responsiveness by TRPV1 antagonists (SB‐705498 and PF‐04065463) in the unanaesthetized, ovalbumin‐sensitized guinea pig , 2012, British journal of pharmacology.

[61]  E. Burcher,et al.  Acid and stretch, but not capsaicin, are effective stimuli for ATP release in the porcine bladder mucosa: Are ASIC and TRPV1 receptors involved? , 2012, European journal of pharmacology.

[62]  J. Smith,et al.  Antitussive effects of memantine in guinea pigs. , 2012, Chest.

[63]  J. Gever,et al.  AF‐353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist , 2010, British journal of pharmacology.

[64]  S. Spector,et al.  Acute cough: a diagnostic and therapeutic challenge , 2009, Cough.

[65]  E. Delay,et al.  Double P2X2/P2X3 purinergic receptor knockout mice do not taste NaCl or the artificial sweetener SC45647. , 2009, Chemical senses.

[66]  S. Shimada,et al.  P2X2‐ and P2X3‐positive fibers in fungiform papillae originate from the chorda tympani but not the trigeminal nerve in rats and mice , 2009, The Journal of comparative neurology.

[67]  N. Alexis,et al.  Extracellular purines are biomarkers of neutrophilic airway inflammation , 2008, European Respiratory Journal.

[68]  F. Di Virgilio,et al.  Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells , 2007, Nature Medicine.

[69]  J. Kamei,et al.  Involvement of ionotropic purinergic receptors in the histamine-induced enhancement of the cough reflex sensitivity in guinea pigs. , 2006, European journal of pharmacology.

[70]  J. Kamei,et al.  Involvement of P2X receptor subtypes in ATP-induced enhancement of the cough reflex sensitivity. , 2005, European journal of pharmacology.

[71]  T. Finger,et al.  ATP Signaling Is Crucial for Communication from Taste Buds to Gustatory Nerves , 2005, Science.

[72]  P. Barnes,et al.  Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. , 2005, Chest.

[73]  G. Burnstock,et al.  Localization of ATP-gated P2X2 and P2X3 receptor immunoreactive nerves in rat taste buds. , 1999, Neuroreport.

[74]  T. Buday,et al.  Lidocaine, a Non-selective Inhibitor of Voltage-Gated Sodium Channels, Blocks Chemically-Induced Cough in Awake Naïve Guinea Pigs. , 2019, Advances in experimental medicine and biology.

[75]  B. Chizh,et al.  Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. , 2009, Drug discovery today.

[76]  A Pelleg,et al.  Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals. , 1996, The Journal of physiology.